| Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer P Hou, D Liu, Y Shan, S Hu, K Studeman, S Condouris, Y Wang, A Trink, ... Clinical cancer research 13 (4), 1161-1170, 2007 | 510 | 2007 |
| Interaction of imatinib with human organic ion carriers S Hu, RM Franke, KK Filipski, C Hu, SJ Orwick, EA De Bruijn, H Burger, ... Clinical Cancer Research 14 (10), 3141-3148, 2008 | 269 | 2008 |
| Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer S Hu, D Liu, RP Tufano, KA Carson, E Rosenbaum, Y Cohen, EH Holt, ... International journal of cancer 119 (10), 2322-2329, 2006 | 268 | 2006 |
| Uncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors G Wu, E Mambo, Z Guo, S Hu, X Huang, SM Gollin, B Trink, PW Ladenson, ... The Journal of Clinical Endocrinology & Metabolism 90 (8), 4688-4693, 2005 | 264 | 2005 |
| Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant D Liu, S Hu, P Hou, D Jiang, S Condouris, M Xing Clinical Cancer Research 13 (4), 1341-1349, 2007 | 230 | 2007 |
| Crenolanib is active against models of drug-resistant FLT3-ITD− positive acute myeloid leukemia EI Zimmerman, DC Turner, J Buaboonnam, S Hu, S Orwick, MS Roberts, ... Blood, The Journal of the American Society of Hematology 122 (22), 3607-3615, 2013 | 217 | 2013 |
| Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters S Hu, Z Chen, R Franke, S Orwick, M Zhao, MA Rudek, A Sparreboom, ... Clinical Cancer Research 15 (19), 6062-6069, 2009 | 201 | 2009 |
| Pharmacogenetic pathway analysis of docetaxel elimination SD Baker, J Verweij, GA Cusatis, RH Van Schaik, S Marsh, SJ Orwick, ... Clinical Pharmacology & Therapeutics 85 (2), 155-163, 2009 | 200 | 2009 |
| Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide EI Zimmerman, S Hu, JL Roberts, AA Gibson, SJ Orwick, L Li, ... Clinical Cancer Research 19 (6), 1458-1466, 2013 | 175 | 2013 |
| High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes V Vasko, S Hu, G Wu, JC Xing, A Larin, V Savchenko, B Trink, M Xing The Journal of Clinical Endocrinology & Metabolism 90 (9), 5265-5269, 2005 | 156 | 2005 |
| A phosphotyrosine switch regulates organic cation transporters JA Sprowl, SS Ong, AA Gibson, S Hu, G Du, W Lin, L Li, S Bharill, ... Nature communications 7 (1), 10880, 2016 | 136 | 2016 |
| Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy S Guo, M Vieweger, K Zhang, H Yin, H Wang, X Li, S Li, S Hu, ... Nature communications 11 (1), 972, 2020 | 135 | 2020 |
| Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance JA Sprowl, L van Doorn, S Hu, L Van Gerven, P de Bruijn, L Li, AA Gibson, ... Clinical Pharmacology & Therapeutics 94 (5), 585-592, 2013 | 115 | 2013 |
| Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions N Pabla, AA Gibson, M Buege, SS Ong, L Li, S Hu, G Du, JA Sprowl, ... Proceedings of the National Academy of Sciences 112 (16), 5231-5236, 2015 | 110 | 2015 |
| Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel AJM de Graan, CS Lancaster, A Obaidat, B Hagenbuch, L Elens, ... Clinical Cancer Research 18 (16), 4433-4440, 2012 | 100 | 2012 |
| Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase RM Franke, AM Kosloske, CS Lancaster, KK Filipski, C Hu, O Zolk, ... Clinical Cancer Research 16 (16), 4198-4206, 2010 | 94 | 2010 |
| Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer S Hu, M Ewertz, RP Tufano, M Brait, AL Carvalho, D Liu, AP Tufaro, ... The Journal of Clinical Endocrinology & Metabolism 91 (1), 98-104, 2006 | 85 | 2006 |
| Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy S Hu, KM Huang, EJ Adams, CL Loprinzi, MB Lustberg Clinical Cancer Research 25 (21), 6295-6301, 2019 | 84 | 2019 |
| Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells B Lu, L Wang, C Stehlik, D Medan, C Huang, S Hu, F Chen, X Shi, ... The Journal of Immunology 176 (11), 6785-6793, 2006 | 79 | 2006 |
| Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics CS Lancaster, JA Sprowl, AL Walker, S Hu, AA Gibson, A Sparreboom Molecular cancer therapeutics 12 (8), 1537-1544, 2013 | 76 | 2013 |
Alex SparreboomProfessor and Lucius A. Wing Chair, The Ohio State UniversityDirección de correo verificada de osu.edu